This could explain the synergy of checkpoint inhibitors and epigenetics as seen in the study by Kim et al. This theory is supported clinically in melanoma where MHC II expression predicted response to anti-PD-1/PD-L1 therapy [30]. Here, CD274 is linked to melanoma.